Brief: Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373
18/10/2023 13:26
Oct 18 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES INITIATES GLP TOXICOLOGY & SAFETY
PHARMACOLOGY STUDIES FOR LEAD CANDIDATE EB-373, A NEXT
GENERATION PSILOCIN PRODRUG TARGETING PSYCHIATRIC DISORDERS
Source text for Eikon: ID:nBw309N30a
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003